Efficacy of ultra-low-dose (0.1  mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series.

CONCLUSION:: Intravitreal injection of ultra-low-dose ranibizumab showed promising efficacy and good ocular safety. However, further large-scale studies are required to give stronger evidence about the efficacy and safety of ultra-low-dose ranibizumab. PMID: 30428702 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research